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Le principe des droits de la personne 
sur la transparence et l’équité doivent 
servir de guides aux politiques et activ-
ités des compagnies pharmaceutiques. 
Cet article examine la transparence du 
processus d’approbation des drogues et de 
l’égalité des sexes dans les essais cliniques. 
Les auteurs ont révélé un manque de 
transparence dans les approches de Santé 
Canada dans les décisions de régulation 
des médicaments et une sous-représen-
tation des femmes dans les recherches 
cliniques importantes.
Clinical trials are crucial when it 
comes to determining the benefits 
and risks of pharmaceutical treat-
ments. The human rights principles 
of transparency and equality are 
intended to guide pharmaceutical 
companies and government agencies 
in the development of policies per-
taining to the release of drug infor-
mation and establishment of equal 
opportunities for men and women 
to partake in trials. Representation 
of both sexes is necessary so that 
research outcomes can be analyzed 
and attributed accordingly. Thus, 
preventing harm and improving 
patient care. This paper examines 
the transparency of the drug approval 
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process and gender equality in clinical 
research since the implementation of 
Canadian policies. A feminist social 
justice perspective is used to highlight 
current industry practices around 
access to health care information and 
women’s involvement in trials. A con-
tent literature review is used to gather 
information about the research in 
this paper. Our findings reveal a 
continual lack of transparency behind 
Health Canada’s approaches to drug 
regulatory decisions and an ongoing 
underrepresentation of women in 
important clinical research. This dis-
turbing pattern reveals both ethical 
and justice concerns.
Introduction
Human rights are concerned with the 
attainment of the highest standard 
of physical and mental health for 
all people. According to the Human 
Rights framework,
Two key human rights principles, 
transparency and equality, are meant 
to guide policies and actions of health 
care systems (UNPFA). In relation 
to pharmaceutical companies, the 
adoption of these principles to 
policies and mission statements 
should influence the development 
and release of drugs (Khosla and 
Hunt). This paper examines the 
transparency of the drug approval 
process as well as gender equality 
in clinical trials. The right to health 
cannot be fully realized without 
access to unbiased information 
from pharmaceutical companies 
and government agencies. Without 
knowledge, healthcare professionals 
are unable to make evidence-based 
decisions regarding prescriptions 
for their patients, putting them 
at risk for adverse health events. 
Furthermore, drug outcomes must 
be properly analyzed and attributed 
to the correct population in order to 
determine safety and effectiveness. 
This paper will examine Health 
Canada’s documents and policies, 
including the Summary Basis of 
Decision (SBD) documents, the 
Guidance Document on the Inclusion of 
Women in Clinical Trials (1997), and 
its revision in 2013, and the Health 
Portfolio Sex and Gender-Based Analy-
sis Policy (2009). With reference to the 
scholarly literature these documents 
will be analyzed to determine whether 
policy and policy implementation in 
all these areas has improved.
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Methodology
This paper will use a feminist social 
justice lens to examine the frame-
works that endeavour to elucidate 
women’s underrepresentation in 
clinical research. The feminist ethics 
framework analyzes the norms and 
assumptions that govern research 
through a perspective that allows us 
to understand how research practices 
involving and affecting women have 
undervalued and harmed them. Con-
temporary feminist frameworks have 
illuminated past theories in order to 
bring about present views. Simone de 
Beauvoir has had significant influence 
on feminist theory by explaining the 
Hegelian concept of “the Other,” 
which refers to what is unfamiliar 
and deviating from the norm (cited 
in Mitchinson). The process of 
“othering” is a type of oppression, 
which is endorsed by those who have 
knowledge as well as power and who 
use these two elements to achieve a 
particular political agenda in its goal 
of domination (Hall). Stemming 
from this concept of “othering,” Susan 
Sherwin, a contemporary feminist 
ethics scholar, appeals to Iris Young’s 
social justice theory, which identifies 
oppression as a form of injustice. 
Young’s notion of social justice rec-
ognizes that oppression on the basis 
of gender translates into injustices in 
the form of marginalization and leads 
to inequitable health care for women 
(cited in Sherwin).
 
Human Rights and 
Pharmaceutical Transparency
The International Covenant on Eco-
nomic, Social and Cultural Rights 
(UN Economic and Social Council) 
describes health as a fundamental 
human right. It provides examples of 
state parties’ obligations to adopting 
health as a right and defines the 
principles of accessibility, availability, 
acceptability, accountability, quality, 
non-discrimination, transparency, 
and participation. In the context of 
pharmaceuticals, access to pharma-
ceutical information regarding the 
safety and efficacy of tested drugs 
can be linked to the principle of 
transparency (Khosla and Hunt). By 
all accounts, transparency means that 
governments must be open about all 
information and decision-making 
processes related to rights. People 
must be able to know and understand 
how major decisions affecting rights 
are made and how public institu-
tions, such as hospitals and schools, 
which are needed to protect rights, 
are managed and run (NESRI). Un-
fortunately, mandating this principle 
to clinical trial registration and access 
to outcome information has been a 
challenge. 
Various initiatives have been em-
ployed for clinical trial registration, 
such as the establishment of the 
International Clinical Trial Registry 
Platform (ICTRP) by the World 
Health Organization (WHO). 
However, due to lax enforcement 
and limited provision, the imple-
mentation of its recommendations 
and regulations at national/regional 
levels remains deficient (Lemmens 
and Telfer). Another concern is that 
even if clinical trials are registered, 
government agencies protect the 
confidentiality of pharmaceutical 
companies and limit public access 
to safety and effectiveness data. In 
Canada, the government introduced 
the Smart Regulation strategy, which 
assured a speedy process for drug 
approval and made the country a 
very attractive place to conduct trials, 
most of which are sponsored by the 
pharmaceutical companies (Lexchin). 
Equally concerning is the fact that in 
Canada information regarding out-
come data is considered the property 
of pharmaceutical companies which 
may take Health Canada to court 
for disagreements in regulatory plans 
(Silversides).
In a society with such heavy use 
of medication, limited knowledge 
can have disastrous consequences. 
For example, adverse effects from 
drugs contribute to both increased 
emergency room visits and mortality 
from overconsumption in hospital. 
Vioxx, a block buster drug manufac-
tured by Merck, the second-largest 
drug maker in the U.S., was found 
to have caused over 60,000 deaths 
after being illegally promoted for 
the treatment of rheumatoid arthritis 
(Lyon). Vioxx was recalled in 2004, 
but the company’s illegal promotion 
of the drug was considered a simple 
misdemeanour rather than a felony 
by the courts. 
The Women and Health Protection 
(WHP), an alliance of researchers and 
groups concerned with the safety of 
pharmaceutical drugs, warns that 
Health Canada is placing proprietary 
and commercial interests ahead of 
those of the public by withholding 
open access to key clinical trial infor-
mation. For women, the right to re-
productive health services can only be 
truly exercised if they have knowledge 
about possible benefits and risks. Also, 
women typically oversee health care 
decisions for their extended families 
making access to information on drug 
safety paramount. 
In 1998, Health Canada approved 
Diane-35 for the treatment of severe 
acne. Alarmingly, the drug had never 
actually been tested on the population 
for which it was approved—those 
suffering from severe acne. Moreover, 
the drug was being prescribed illegally 
off-label as a birth control pill (Grigg-
Spall). In February 2013, after eleven 
deaths of reportedly otherwise healthy 
women, Health Canada undertook 
a review of the drug. Despite the 
known risk of Diane-35 causing a 
potential serious life-threatening 
blood clot (venous thromboembol-
ism) and knowledge of aggressive 
illegal prescription, Health Canada 
chose to allow continued use. The 
VOLUME 33, NUMBERS 1,2 137
benefits of the drug were deemed 
to outweigh its risks. This case is an 
obvious illustration of Health Can-
ada’s responsiveness to commercial 
interests rather than public interests.
Policy Development Pertaining 
to Pharmaceutical Transparency
In 2004, Health Canada introduced 
Phase I of the Summary Basis of 
Decision (SBD) documents. These 
documents were meant to improve 
the transparency of the drug approval 
process by making clinical trial infor-
mation available to the public (Habibi 
and Lexchin). Their information was 
meant to aid clinicians and patients 
in making unbiased and informed 
decisions regarding the prescription 
of drugs. A recent study found that 
the SBD documents provide incon-
sistent and incomplete information 
with regards to the characteristic 
of patients (sex and age) on which 
the drugs were evaluated and little 
disclosure about the potential risks 
and benefits. The Auditor General 
of Canada also concluded that 
Health Canada did not fulfill long 
standing promises to increase the 
transparency of approved clinical 
trials. This is a cautionary warning 
that evidence-based information with 
regards to the safety and effectiveness 
of recently marketed drugs is still not 
at the disposal of physicians. Thus, 
Canadians should be skeptical when 
taking newly released prescription 
medication. Phase II of the SBD 
documents was launched in June of 
2012 with revisions, including the 
restyling of the documents to a user 
friendly, web-based, as well as ques-
tion and answer format; a proposed 
shorter time to publish the documents 
(twelve weeks instead of twenty); and 
more information focusing on a risk 
and benefit analysis for both drugs 
and medical devices. However, it 
remains unclear if more information 
about the results and characteristics 
of the clinical trials will be published. 
In 2013 the Harper Government 
introduced Bill C-17, or Vanessa’s 
law, after a fifteen-year-old girl died 
from side effects of the prescribed 
drug, Cisapride, in 2000 (Herder, 
Gibson, Graham, Lexchin and 
Mintzes). The bill is meant to im-
prove drug safety by giving Health 
Canada legislative powers to recall 
drugs, increase fines, compel com-
panies to do post-market research, 
and make adverse event reporting 
mandatory in health care facilities. 
In theory, the bill should bring about 
legal change. In practice, however, 
changing a longstanding culture of 
protecting the confidentiality of 
pharmaceutical information will be 
challenging. According to Health 
Minister Rona Ambrose, drug manu-
facturers “may” disclose clinical trial 
information in order to protect 
public safety (cited in Herder et al. 
289). In other words, “the Health 
Minister may suspend a manufac-
turer’s license to sell a drug, but he 
or she cannot require the drug to 
be recalled from pharmacy shelves, 
only the manufacturer can do so” 
(288). Thus, at this time, there are 
no guarantees. Whether and how 
this bill will actually be enforced 
and protect Canadians from unsafe 
drugs remains to be seen.
Health Equity and Gender 
Equality in Clinical Trials
Health equity is concerned with the 
attainment of equal opportunities for 
good health and high-quality care for 
all people. It requires continuous so-
cial and political effort to address his-
torical and contemporary injustices 
and eliminate disparities in health 
care to ensure that everyone is valued 
equally. The different life experiences 
and needs of men and women must 
be taken into consideration when 
developing programs and policies in 
society. In all societies socially con-
structed, gender-based disparities all 
too frequently exist that disadvantage 
women, impeding their development. 
Since 1982, the Canadian Charter of 
Rights and Freedoms, has asserted 
the principle of equality allowing 
affirmative action programs to erad-
icate disadvantages (Hogg). In spite 
of years of effort, overall progress in 
improving women’s equality has been 
inconsistent as women are still under-
represented in all levels of leadership 
and other decision-making domains. 
In a traditionally male-dominated la-
bour market, women, especially those 
with less education, are more likely 
to occupy lower paying jobs such as 
cleaning, care work, as well as contract 
or part-time work. Women also bear 
the burden of a dual work day, often 
limiting their ability to participate 
equally in the labour market as well 
Health equity is concerned with the attainment of equal opportunities 
for good health and high-quality care for all people. It requires 
continuous social and political effort to address historical and 
contemporary injustices and eliminate disparities in health care 
to ensure that everyone is valued equally. 
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as in other opportunities in society 
(Messing and Ostlin). 
When it comes to pharmaceuticals, 
health equality requires including 
women and men equally in drug 
trials so that safety, effectiveness and 
tolerance of drugs can be tested and 
outcomes can be attributed appro-
priately. Researchers must consider 
the pharmacokinetic and pharma-
codynamics differences between the 
sexes that stem from variations in 
body size, composition, and differ-
ences in hormones. The higher fat 
content and smaller average body 
size of women typically result in 
higher concentrations of a given drug 
circulating in their blood as compared 
to men’s for a period of time, leading 
to varied drug responses (Merkatz, 
Temple, Sobel, Feiden and Kessler). 
For example, a study done by Paul 
Ridker et al. showed that aspirin 
has different effects on women with 
regard to primary protection against 
stroke and heart attacks. Aspirin 
lowered the risk of stroke but did not 
affect the risk of myocardial infarction 
or death when consumed by women 
as opposed to men. Women can only 
reap the benefits of pharmaceuticals if 
they have been included in the testing.
Furthermore, not only biological 
but socially constructed gender-based 
differences must be reflected as they 
likewise account for differences in 
drug outcomes. Epidemiologically, 
certain medical conditions are unique 
to women (Doyal). For example, they 
are twice more likely to experience 
depression at some point in life than 
men (Nolen-Hoeksema). This can 
be attributed to gender roles which 
place the additional stresses of work 
and home responsibilities on women, 
including caring for children and the 
elderly. Also, gynaecological exams are 
generally excluded in studies of AIDS 
even though infected women most 
often present with chronic gynaeco-
logical problems (DeBruin). Thus, 
achieving an equitable representation 
and analysis of both biological and 
gender-based differences of women 
in clinical trials is imperative for 
their welfare. 
Historical Context and Policy 
Development
The history of women’s participation 
in clinical trials can be read in policies 
and regulations. Policy development 
in the area of protection of human 
research participants began in 1949 
with the issuance of the Nuremberg 
Code, which outlined research ethics 
principles in response to flagrantly 
offensive human experimentation 
conducted by the Nazis during World 
War II (Pauker). This document as 
well as the related declaration of 
Helsinski formed the basis for Health 
Canada and U.S. research regulations 
(Mandal, Acharya and Parija). In the 
mid-1900s, health problems caused 
by the drugs thalidomide and diethyl-
stilbestrol (DES) signified abuse and 
brought about a public awareness of 
the need for greater protection for 
fetuses from hazards in medicine. 
In response, in the late 1970s, the 
U.S. Food and Drug Administration 
(FDA) adopted a policy of exclusion 
entitled “General Considerations for 
the Clinical Evaluation of Drugs,” 
recommending that premenopausal 
women capable of becoming pregnant 
be excluded from participating in 
Phase I and early Phase II of drug 
trials (U.S. Food and Drug Admin-
istration). While this policy was 
supposed to refer only to women of 
childbearing years and early phases 
of clinical trials, it quickly led to 
all women being excluded from all 
pharmaceutical research for nearly 
two decades (Lippman). 
In the 1980s, AIDS activists 
working to promote entry to trials 
for AIDS therapies were successful 
in receiving access to experimental 
drugs used to treat the serious and 
life-threatening illness (Mastroianni, 
Faden and Federman). Women’s 
advocacy continued with the rec-
ognition that clinical outcomes of 
medications given to women and 
men were only evaluated in men. 
Concerns over the lack of research 
on breast and reproductive cancers 
amplified lobbying for the inclusion 
of women in clinical trials and in 
1997 led to the development of the 
Canadian Guidance Document on 
the Inclusion of Women in Clinical 
Trials (Lippman). The policy rec-
ommended that women should be 
included in all phases of clinical trials 
in an appropriate sample size that 
would allow for adequate effects of 
drug treatment to be evaluated. This 
was intended to lead to safer prescrip-
tions and decreased adverse health 
consequences in women. Inclusion 
criteria was directed to all women of 
childbearing and post-menopausal 
years and researchers were encour-
aged to include both genders as well 
as to analyze outcomes of treatment 
by sex-related differences. Drug 
manufactures were to guarantee that 
those drugs seeking market approval 
included women at all stages of the 
drug development process, ensuring 
that the full spectrum of risks and 
benefits were captured throughout 
the clinical trial. In 2013, The 
Guidance Document, Considerations 
for Inclusion of Women in Clinical 
Trials and Analysis of Sex Differences, 
was released to supersede the 1997 
document.
In 2000, another initiative, Health 
Canada’s Gender-Based Analysis 
Policy, unveiled its support for a 
gender-based analysis (Fuller). The 
policy goals were to address health 
differences between men and women 
as they pertained to sex and gender 
as well as to understand experiences 
with health and illness and interaction 
with the health care system. This was 
to be accomplished by “identifying 
gender equality issues and proposing 
remedies to inequality in the areas of 
VOLUME 33, NUMBERS 1,2 139
policy and program development or 
implementation, research, funding, 
data collection, surveillance, and 
regulatory activities” (10).
Results of Policies and Status of 
Women in Clinical Trials 
A review of the 1997 Canadian 
Guidance Document on the Inclusion 
and Sinead O’Mahoney reviewed 
nineteen trials between 1990-1999, 
looking at the effects of statin 
drugs on lowering cholesterol and 
decreasing the risk of heart attacks 
and strokes. They found that only 
ten percent of the participants were 
women and none were over the age 
of seventy-five. Statistically, the fastest 
growing infected population from 
Madeline Boscoe investigated the 
use of GBA in thirty-eight Cochrane 
systematic reviews of cardiovascular 
health, finding that GBA was largely 
lacking in the examined literature. 
All of the above findings have ser-
ious medical implications for women 
and have led the Canadian Research 
Ethics Boards (REBs) examiners to 
review the various assumptions or 
of Women in Clinical Trials noted that 
the policy guidelines for researchers 
served merely as recommendations 
with no mandatory requirement 
to conform (Lippman). While The 
Women’s Health Strategy of Health 
Canada promised to monitor the in-
clusion of women in clinical trials this 
endeavour was never mandated or put 
into practice. In comparison, guide-
lines from the National Institutes of 
Health (NIH) in the U.S. made it a 
requirement for researchers to include 
women in clinical trials if they were 
to be funded. However, despite the 
prerequisite of the established guide-
lines, various investigators, including 
the General Accounting Office in the 
U.S., found a continuing under-rep-
resentation of women in clinical trials 
in the country. Considering that the 
U.S. National Institute of Health 
failed to bring about change despite 
having an actual requirement for 
inclusion, it should not be a surprise 
that Canada, with recommended 
guidelines only, has also failed. In 
fact, neither the U.S. nor Canadian 
policies enforced monitoring provi-
sions for the strategies. 
A study conducted by Saumyadwip 
Bandyopadhyay, Anthony Bayer, 
AIDS is women (Dresser). Yet from 
2000 to 2008, HIV-infected women 
accounted for only 20 percent of 
participants in antiretroviral therapy 
clinical trials in the U.S. (Soon et al.). 
Reshma Jagsi et al. reviewed 661 can-
cer research studies for seven non-sex 
specific types of cancers. They found 
a lower percentage of women were 
included in the research than were 
being diagnosed with the particular 
cancer in the general population. 
In 2010, the Institutional Review 
Board (IRB) and other researchers 
concluded that pregnant women 
continue to be excluded in clinical 
trials despite policy changes (Levin). 
The Gender Based Analysis Policy 
(GBAP) makes no mention that 
gender and sex based differences 
must be analyzed separately for their 
impact on the experiences of women 
taking medication to be known. A 
study conducted at the University of 
British Columbia’s Centre for Health 
Services and Policy Research found 
that GBAP was neither adopted nor 
implemented in pharmaceutical 
policy and lacked translation into 
research practice (Greyson, Becu and 
Morgan). Likewise, Marion Doull, 
Vivien Runnels, Sari Tudiver, and 
rationales researchers voice as justifi-
cation for the underrepresentation or 
exclusion of women in their clinical 
trials (Giacomini and Baylis). Com-
mon rationales for these practices, 
include the notions that women a) 
are similar to men biologically and 
results can be generalized to them; 
b) are privileged to avoid potential 
hazardous outcomes in research; c) 
introduce too much variability and 
confusion for result interpretation; d) 
are hard to recruit and retain; e) add 
expense due to increased sample size; 
and f ) pose a liability risk if pregnant. 
In March 2013, Health Canada re-
leased its updated version of the Guid-
ance Document for Considerations for 
Inclusion of Women in Clinical Trials 
and Analysis of Sex. The document ac-
knowledged that women’s partaking 
in clinical research had increased but 
underrepresentation continued to be 
visible especially in the early phases 
of trials. Furthermore, pregnant and 
breastfeeding women continue to be 
excluded leading to misinformation 
and safety concerns about the effects 
of treatments. However, as was noted 
in the 1997 review, the guideline 
continues to serve merely as a rec-
ommendation to drug sponsors. It 
The policy recommended that women should be included in all phases of 
clinical trials in an appropriate sample size that would allow for adequate 
effects of drug treatment to be evaluated. This was intended to lead to 
safer prescriptions and decreased adverse health consequences in women. 
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has still not been made mandatory to 
include women and there is no clear 
indication as to how or if monitoring 
provisions will be enforced. 
A more recent study examined 
the reporting of sex and gender in 
randomized controlled trials (RCT) 
across Canada during the period of 
January 2013 – July 2014. The results 
demonstrated poor analysis of sex and 
gender in all of the reviewed research 
(Welch et al. ). Another study suggests 
that while the overall representation 
of women in clinical trials has indeed 
improved, the routine exclusion of 
pregnant women remains a concern 
(Baylis and Kaposy). Despite the fact 
that during pregnancy two to three 
out of five women use four or five 
medications, there are only a few 
drugs that are labelled for-use during 
pregnancy. Data on dosage and safety 
for most medications on the market 
remains insufficient. In light of these 
findings, the authors suggest a man-
datory shift towards a justification 
model for excluding pregnant women 
from important clinical research. In 
other words, pregnant women should 
be included in research unless there is 
reasonable justification that the tested 
drug will produce harm to either the 
mother or the fetus. 
Conclusion
This paper examined the transparen-
cy of the drug approval process and 
gender equality in clinical research 
since the implementation of Cana-
dian policies. The right to health 
documented by WHO as the right 
to the highest attainable standard of 
physical and mental health cannot 
be fully realized without access to 
unbiased information from phar-
maceutical companies. In theory, 
drug regulatory agencies should be 
responsible and accountable for the 
safety of the public as opposed to 
serving commercial interests. This 
is currently not the case when it 
comes to Health Canada’s approach-
es to the drug regulatory process. 
Although there have been some 
policy developments in the area of 
drug transparency with the passing 
of the SBD documents and Bill-17, 
it remains to be determined whether 
recommendations will be enforced to 
protect Canadians from unsafe drugs. 
Furthermore, Health Canada 
still does not require the inclusion 
in trials of specific populations 
with less than optimal potential to 
demonstrate a drug’s effectiveness. At 
this time, Health Canada guidelines 
recommending for women, including 
those who are pregnant to be equally 
included in clinical trials and federal 
government commitments to Gender 
Based Analysis in research is not being 
effectively implemented. Women, 
especially those who are pregnant, 
continue to be underrepresented or 
excluded from important clinical 
research resulting in a lack of informa-
tion regarding vital health outcomes. 
The literature suggests that cultural 
biases continue to shape medical re-
search and unethical and oppressive 
practices are still present. 
Drug transparency and the inclu-
sion of women in research is ethically 
imperative as it advances justice by 
preventing harm and improving the 
quality of research where the goal is 
to ensure safe and equitable health 
outcomes for women and men. At 
this time, the human rights principles 
of transparency and equality are not 
being mandated in the pharma-
ceutical industry by the Canadian 
government.
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The key turning in the lock
Never sure 
What I’ll find.
Not dangerous, they said, never meeting my eye.
A metallic clunk as the tumblers slide, and I snake
My arm into the widening crevice and knock lightly on the inside of
The peeling grey door, like they said to do.
Ease myself into the room, and on impulse, begin gently
Singing his name.
Damp, felt-wrapped silence, the light
Dim and filtered as I adjust and make my way to the drapes, 
drawn back,
Startling dust and random particles in the sudden sunlight.
Softer now, low and lilting, my voice singing his name and filling
That empty space like a caress.
The big mahogany clock ticks down the hall, it’s face stark and
White, distorted numerals twisted on the dial when I hear
A slight whimpering and the hair on my
Neck prickling as I slowly become aware…   
where….  (my eyes darting)
Where are you…  
Images and fears shatter my thoughts, and then a grip,
A sudden pull, the loud crack of my bones 
and as my eyes open,
I can smell him, dark, under the bed, still holding my leg, a
sickening loosening in my gut, I can’t scream, his dilated pupils
and shoulders trembling and shuddering and 
shock, self-injury, illness, I’m still assessing the patient 
when I see the shining, red
gleaming drops,  
and then a perfect, 
velvet 
silence 
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